The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Whole genome sequencing of cfDNA as a non-invasive method for MRD detection in multiple myeloma
Dory Abelman, PhD(c), Princess Margaret Cancer Centre, Toronto, Canada, discusses efforts to create less invasive methods for detecting measurable residual disease (MRD) in multiple myeloma through the use of whole genome sequencing (WGS) of cell-free DNA (cfDNA). He highlights the benefits of this approach, such as avoiding bone marrow aspirates and improving detection of patchy and extramedullary disease. Mr Abelman goes on to highlight preliminary results from an analysis which compared various MRD detection techniques in a cohort of patients in the MM Molecular Monitoring (M4) study. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
